Pharming Group N.V. H1 2022 Financial Results Analyst Call August 4, 2022 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM 1177 Forward looking statements 2 This presentation may contain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our clinical results and other future condit ...

Pharming Group N.V. (OTCPK:PHGUF) Q1 2022 Earnings Conference Call May 12, 2022 7:30 AM ET Company Participants Sijmen de Vries - CEO Jeroen Wakkerman - CFO Anurag Relan - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C. Wainright Hartaj Singh - Oppenheimer & Co. Christian Glennie - Stifel Simon Scholes - First Berlin Equity Operator Hello, everyone, and welcome to the Pharming's First Quarter Results Conference Call. My name is Victoria, and I'll be coordinating your call today. [Ope ...

[SEC Filing Information](index=1&type=section&id=SEC%20Filing%20Information) [Filing Details](index=1&type=section&id=Filing%20Details) This section identifies the filing as a Form 6-K for Pharming Group N.V. for April 2022, indicating its status as a foreign private issuer filing under Form 20-F - Pharming Group N.V. filed a **Form 6-K** for April 2022 as a foreign private issuer under Form 20-F[1](index=1&type=chunk)[2](index=2&type=chunk) [Exhibit Index](index=2&type=section&id=EXHIBIT%20INDEX) The exhibit index specifies that a press release announcing the filing of the 2021 Annual Report and Form 20-F, and the convening of the 2022 AGM, is filed as Exhibit 99.1 - **Exhibit 99.1** is a press release announcing the filing of the 2021 Annual Report, Form 20-F, and the 2022 AGM[4](index=4&type=chunk)[6](index=6&type=chunk) [Signature](index=2&type=section&id=SIGNATURE) The report is officially signed by Sijmen de Vries, CEO of Pharming Group N.V., on April 7, 2021 - The report was signed by **Sijmen de Vries**, CEO of Pharming Group N.V., on April 7, 2021[7](index=7&type=chunk)[9](index=9&type=chunk) [Company Announcement](index=3&type=section&id=Company%20Announcement) [Filing of 2021 Annual Report and Form 20-F](index=3&type=section&id=Pharming%20announces%20the%20filing%20of%20its%202021%20Annual%20Report%2C%20with%20Form%2020-F%20also%20filed%20with%20the%20U.S.%20Securities%20and%20Exchange%20Commission%20and%20convenes%20its%202022%20AGM) Pharming Group N.V. announced the filing of its Annual Report for the year ended December 31, 2021, and its Form 20-F with the U.S. SEC, making both documents available on the company's website - Pharming Group N.V. filed its **2021 Annual Report** and **Form 20-F** with the U.S. SEC for the period ended December 31, 2021[10](index=10&type=chunk) - The Annual Report and Form 20-F are available on the Company's website under Investors/Financial Documents and Investors/SEC filings, respectively[11](index=11&type=chunk) [Convening of 2022 Annual General Meeting (AGM)](index=3&type=section&id=2022%20AGM) The company announced its 2022 Annual General Meeting (AGM) will be held on Wednesday, May 18, 2022, at 2:00 pm (CEST), with all relevant meeting documents available on its website - The **2022 Annual General Meeting (AGM)** is scheduled for Wednesday, May 18, 2022, at 2:00 pm (CEST)[11](index=11&type=chunk) - Meeting documents, including the Notice to Convene, Explanatory Notes, and Form of Proxy, are available on the company's website[11](index=11&type=chunk) [About Pharming Group N.V.](index=3&type=section&id=About%20Pharming%20Group%20N.V.) [Company Overview](index=3&type=section&id=Company%20Overview) Pharming Group N.V. is a global, commercial-stage biopharmaceutical company dedicated to developing innovative protein replacement therapies and precision medicines for rare diseases and unmet medical needs - Pharming Group N.V. is a global, commercial-stage biopharmaceutical company[12](index=12&type=chunk) - The company focuses on developing innovative protein replacement therapies and precision medicines for rare diseases and unmet medical needs[12](index=12&type=chunk) [Product Portfolio and Pipeline](index=3&type=section&id=Product%20Portfolio%20and%20Pipeline) Pharming's portfolio is anchored by its recombinant human C1 esterase inhibitor (rhC1INH) franchise, including RUCONEST®, and a pipeline featuring leniolisib for APDS, a strategic collaboration for OTL-105, and preclinical development for Pompe disease [RUCONEST® (rhC1INH) Franchise](index=3&type=section&id=RUCONEST%C2%AE) RUCONEST® is a plasma-free recombinant human C1 esterase inhibitor approved for acute hereditary angioedema attacks, with ongoing investigations for additional indications - **RUCONEST®** is the first and only plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy[13](index=13&type=chunk) - It is approved for the treatment of acute hereditary angioedema (HAE) attacks and commercialized in the US, EU, UK, and other regions[13](index=13&type=chunk) - Pharming is investigating rhC1INH for additional indications, including pre-eclampsia, acute kidney injury, and severe pneumonia from COVID-19[14](index=14&type=chunk) [Leniolisib (PI3K delta inhibitor)](index=3&type=section&id=Leniolisib) Leniolisib, an oral PI3K delta inhibitor, is under study for activated PI3K delta syndrome (APDS), having met primary endpoints in a Phase 2/3 study, with global regulatory filings targeted from Q2 2022 - **Leniolisib**, an oral phosphoinositide 3-kinase delta (PI3K delta) inhibitor, is being studied for activated PI3K delta syndrome (APDS)[15](index=15&type=chunk) - Leniolisib met both primary endpoints in a registration-enabling Phase 2/3 study in the US and Europe[15](index=15&type=chunk) - Global regulatory filings for leniolisib are targeted from **Q2 2022** onwards[15](index=15&type=chunk) [Strategic Collaborations and Next-Generation Therapies](index=3&type=section&id=Strategic%20Collaborations%20and%20Next-Generation%20Therapies) Pharming collaborates with Orchard Therapeutics on OTL-105 for HAE and develops next-generation protein replacement therapies, including a preclinical program for Pompe disease - Pharming collaborates with Orchard Therapeutics on OTL-105, an ex-vivo autologous hematopoietic stem cell (HSC) gene therapy for HAE[16](index=16&type=chunk) - The company is developing next-generation protein replacement therapies using its transgenic manufacturing technology, including a preclinical program for Pompe disease[17](index=17&type=chunk) [Disclaimers and Contact Information](index=4&type=section&id=Disclaimers%20and%20Contact%20Information) [Forward-looking Statements](index=4&type=section&id=Forward-looking%20Statements) This section outlines standard disclaimers regarding forward-looking statements, covering risks and uncertainties related to clinical trials, commercial prospects, COVID-19, and financial resources - The press release contains forward-looking statements regarding clinical trials, commercial prospects, COVID-19 impact, and financial requirements[18](index=18&type=chunk) - These statements are subject to risks and uncertainties described in Pharming's 2021 Annual Report and Form 20-F[18](index=18&type=chunk) [Inside Information and Contacts](index=4&type=section&id=Inside%20Information) This section notes the press release may contain inside information under EU Market Abuse Regulation and provides contact details for company executives and external PR consultants - The press release may contain inside information as per Article 7(1) of the EU Market Abuse Regulation[19](index=19&type=chunk) - Contact information is provided for Pharming Group's CEO, Investor Relations Manager, and FTI Consulting (London/USA) and LifeSpring Life Sciences Communication (Amsterdam) for public inquiries[19](index=19&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Pharming Group N.V. (OTCPK:PHGUF) Full Year 2021 Earnings Conference Call March 17, 2022 9:00 AM ET Company Participants Sijmen Vries - Executive Director and Chief Executive Officer Jeroen Wakkerman - Chief Financial Officer Anurag Relan - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer & Co Joe Pantginis - H.C. Wainright Alex Cogut - Kempen Christian Glennie - Stifle Operator Hello and welcome to Pharming’s Full Year 2021 Results call. My name is Jordan and I’ll be coordinat ...

Pharming Group N.V. (OTCPK:PHGUF) Q3 2021 Results Conference Call October 28, 2021 7:30 AM ET Company Participants Sijmen de Vries - CEO Dr. Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Hartaj Singh - Oppenheimer & Co. Joe Pantginis - H.C. Wainright Simon Scholes - First Berlin Sijmen de Vries Thank you very much. Good morning, good afternoon. Welcome to our nine months 2021 results call. I will be happy taking you through the call with a couple of my colleagues, ...

Pharming Group N.V. (OTCPK:PHGUF) Q2 2021 Earnings Conference Call August 5, 2021 1:00 PM ET Company Participants Sijmen De Vries - Chief Executive Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Joe Pantginis - Wainwright Alex Cogut - Kempen Christian Glennie - Stifel Sijmen De Vries Good afternoon, ladies and gentlemen. I'm sitting here with Chief Financial Officer, Jeroen Wakkerman to take you through the half year results 2021. But before I do that, next slide, please, I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...